Comment from Cythera Bio
AnonymousSupportBusiness
Summary: Melinda B. Chu, CEO and Founder of Cythera Bio, supports the FDA's pilot program to integrate AI into early-phase clinical trials. She argues that the program should initially focus on therapeutically simpler platforms, such as topical or intranasal products, to establish transferable methodologies before moving to more complex modalities like cell and gene therapies.
We applaud the FDA’s efforts to modernize regulatory processes and integrate AI to bring new therapies and options to patients more efficiently and more quickly!
Most products share a large portion of core R&D and regulatory activities. Starting with therapeutically simpler platforms (e.g. topical or intranasal) as early test cases for the AI-Enabled Optimization pilot can generate broadly transferable learnings that can later be applied to more complex modalities (e.g. cell or gene therapy), ultimately accelerating development across the entire pharmaceutical ecosystem.
More details in this technical paper below.
https://doi.org/10.5281/zenodo.20943117
Melinda B. Chu, M.D. M.B.A.
CEO and Founder
Cythera Bio